Nurix Therapeutics (NRIX) Projected to Post Earnings on Thursday

Key Points

• Nurix Therapeutics is expected to report Q3 2026 results after market close on October 8. Analysts project a loss of $0.60 per share and revenue of approximately $24.35 million.
• The company missed expectations in its prior quarter, reporting an $0.81-per-share loss versus an expected $0.73 loss, while revenue of $9.04 million fell short of the $15.29 million estimate.
• Analyst sentiment remains broadly positive: 13 analysts rate the stock a Buy, with a consensus target price of $34.21 versus a recent price of $23.71. However, insiders have sold more than 21,000 shares worth approximately $518,000 over the past three months.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) will likely be announcing its Q3 2026 results after the market closes on Thursday, October 8th. Analysts expect Nurix Therapeutics to post earnings of ($0.6009) per share and revenue of $24.3480 million for the quarter. Individuals can check the company's upcoming Q3 2026 earning report for the latest details on the call scheduled for Thursday, October 8, 2026 at 4:00 PM ET.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.08). The business had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock opened at $23.71 on Thursday. The firm's 50 day moving average price is $25.36 and its two-hundred day moving average price is $20.52. Nurix Therapeutics has a twelve month low of $8.85 and a twelve month high of $28.23. The firm has a market cap of $2.46 billion, a PE ratio of -6.87 and a beta of 1.80.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Hans van Houte sold 4,761 shares of Nurix Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total value of $115,977.96. Following the transaction, the chief financial officer directly owned 40,166 shares of the company's stock, valued at $978,443.76. The trade was a 10.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $25.00, for a total value of $108,900.00. Following the transaction, the insider owned 117,227 shares of the company's stock, valued at approximately $2,930,675. This trade represents a 3.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 21,372 shares of company stock valued at $518,463. Company insiders own 6.70% of the company's stock.

Analyst Upgrades and Downgrades

NRIX has been the topic of several research reports. Jefferies Financial Group upped their target price on Nurix Therapeutics from $41.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, June 8th. BTIG Research reissued a "buy" rating and issued a $32.00 target price on shares of Nurix Therapeutics in a research report on Friday, July 10th. Robert W. Baird increased their price target on shares of Nurix Therapeutics from $26.00 to $33.00 and gave the stock an "outperform" rating in a research note on Thursday, June 18th. Oppenheimer started coverage on shares of Nurix Therapeutics in a report on Monday, June 29th. They set an "outperform" rating and a $28.00 price target on the stock. Finally, Mizuho lifted their price objective on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $34.21.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the body's natural protein-disposal systems to treat cancer and other serious diseases. The company's approach centers on targeted protein modulation, including the use of small molecules to promote the degradation of disease-causing proteins or alter the activity of proteins involved in immune responses.

Nurix's technology platform is built around E3 ligases, enzymes that help determine which proteins are marked for destruction inside cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.